Eisai Vizag plant, one of Eisai’s factories, was established in Andhra Pradesh, India, in December, 2009. Eisai Vizag plant is a high-quality, low-cost manufacturing facility with high cost-competitiveness, supplying medicinal products mainly to emerging and developing countries. GMP (Good Manufacturing Practice) audits, training and technology transfers by teams of experts mainly from Eisai Japan, as well as Eisai US and Eisai Europe are currently ongoing, as this plant also supplies products to developed world markets. It is also taking a role as the manufacturing site of the 2.2 billion diethylcarbamazine citrate (DEC) tablets, an anti-filarial medication which will be provided to WHO at “price zero” until 2020.
Before establishing Eisai Vizag plant, Eisai specialists in the areas of manufacturing, quality control and plant design were selected. Eisai Vizag plant management personnel were then recruited in India and the plant was designed through many discussions among specialists from India and Japan. For manufacturing technology transfer, those highly competent in formulation development were selected from each of the three Eisai plants in Japan and sent to Vizag. Technology transfer documents, with the details of the manufacturing and testing methods and the regulatory approvals, provided from Eisai Japan to Eisai vizag plant, were very useful for smooth technology transfer. Frequent communications were begun among Vizag and other plants in Japan, the US and Europe in Eisai, mainly with regard to the specifications of raw materials, which significantly contributed to stable manufacturing of high quality products.
|Location||East Asia and Pacific, Latin America and Caribbean, Zimbabwe, Zambia, Tuvalu, Timor-Leste, Sao Tome and Principe, Samoa, Papua New Guinea, Nepal, Micronesia, Malaysia, Laos, Kiribati, Kenya, Indonesia, India, Haiti, Gambia, Fiji, Egypt, Dominican Republic, Comoros, Brazil, Bangladesh, Southern Africa, South Asia, North Africa and Middle East|